Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMT2F Natural History Study Nears Full Recruitment as Biomarker Analysis Begins
…Iowa coordinator at CMTRes@healthcare.uiowa.edu to become the final participant. Register with Patients as Partners in Research Today Not yet registered with Patients as Partners in Research? Click the button below…
2023 CMTA-STAR Celebrating our Collective Achievements
Significant Research Investment Made in 2023: We are excited to share that in 2023, the CMTA has ongoing and committed investments of $5,000,00 in research dedicated to finding effective treatments…
CMTA-INC Strategic Alliance Announces the 2025 Inherited Neuropathy Fellowship
…experience in all aspects of clinical research related to inherited neuropathies. Conduct an in-depth research project aligned with their specific interests. Train at one of the INC’s premier research centers,…
Vera Fridman, MD joins the CMTA STAR Advisory Board
…and Associate Director of Medical Student Education for the Department of Neurology. Dr. Fridman has a long-standing clinical and research interest in peripheral neuropathy, her research to date has focused…
CMTA Seed Money Draws NIH Support For Type 2 Gene Editing
…the CMTA’s research efforts are consolidated under the banner of STAR—which brings together the world’s largest network of biotech research partners, research scientists, clinicians and patients—and funds more CMT grants…
Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of Excellence
…soon contact our Patients as Partners in Research who match the study criteria for NMD Pharma’s SYNAPSE-CMT trial. CMTA will contact only those who consent to receive research opportunity notifications….
DNA-Based Therapeutics: A Promising Future for CMT2E Treatment
Researchers at the University of Miami, supported by the Charcot-Marie-Tooth Association (CMTA) and its Strategy To Accelerate Research (STAR) and led by CMTA-STAR Advisory Board member Mario Saporta, MD, PhD,…
CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C
…Research Today Not yet registered with Patients as Partners in Research? Click the button below to register today! Registering ensures you are the first in line for any CMT research…
CMTA 2024 Year in Review_6_SPREADS
Community Partnership Opportunities
…to present 2-3 levels of our overall proposal to a potential sponsor. Do your research on what they have given to other charities locally and pick the levels you feel…